^
Association details:
Biomarker:BRAF fusion
Cancer:Glioma
Drug:Koselugo (selumetinib) (MEK inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
06/04/2021
Excerpt:
Glioma: Recurrent or progressive Disease… MEK inhibitors…Selumetinib (for PA with BRAF fusion or BRAF V600E activating mutation)
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

Excerpt:
...Plasma drug concentrations and pharmacokinetic parameters (Phase I)`Stratum-specific progression-free survival distribution (PFS) (phase II)`Presence or absence of BRAF V600E mutations or BRAF KIAA1549 fusion (phase II)`Progression-free survival (retreatment study)...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

AZD6244 in Children With Low-Grade Gliomas

Excerpt:
...- Stratum 1: Patients with progressive, recurrent or refractory pilocytic astrocytoma with pre-trial tumor material available and with a BRAF aberration i.e. BRAF (V600E) mutation and/or BRAF KIAA1549 fusion as determined by IHC and FISH, respectively. ...
Trial ID: